- All
- Product Name
- Product Keyword
- Product Model
- Product Summary
- Product Description
- Multi Field Search
 |
1609393-89-6
C6H5Cl2N3O
209.04
98.0% min (HPLC)
Light yellow solid
Psoriasis
Deucravacitinib
11/7/2033 (Deucravacitinib)
tyrosine kinase 2
N
2023
ISO 9001;ISO 14001
Supply Chain
Based on the proriasis market analysis, the 2023 demand for this intermediate 4,6-dichloro-N-(trideuteriomethyl)pyridazine-3-carboxamide (CAS No. 1609393-89-6) was esimated to be 4.45 Kg, depending on the specific route. Considering the deeper market penetration and the completion of Deucravacitinib clinical trials on other diseases, the demand is to grow.
As of July 29, 2024, there are 39 potential suppliers manufacturing Deucravacitinib intermediate 4,6-dichloro-N-(trideuteriomethyl)pyridazine-3-carboxamide (CAS No. 1609393-89-6), including 31 factories and 5 labs, among which:
- The 25th percentile has an average registered capital of 1 million CNY;
- The 50th percentile has an average registerd capital of 2.1 million CNY;
- The 75th percentile has an average registered capital of 10 million CNY.
Feeling overwhelmed? Contact Unibest if you need us to quality-check other sources to strengthen your supply chain or to find a tailored solution for your specific procurement request.
Usage and ROS Analysis
Deucravacitinib, CAS No. 1609392-27-9, is a deuterated compound, and structurally speaking, four scaffolds can be identified:
- a benzene - triazole scaffold (scaffold A)
- a deuterated pyridazine (scaffold B + scaffold C)
- a three membered ring (scaffold D)
This compound, 4,6-dichloro-N-(trideuteriomethyl)pyridazine-3-carboxamide, CAS No. 1609393-89-6, is a deuterated compound and it contributes to the pyridazine scaffold of Deucravacitinib as shown below. With this intermediate, no further deuteration is needed.
The chloride group on this Deucravacitinib intermediate is to react with the amine group on the scaffold A (CAS No. 1609394-10-6), forming the backbone of Deucravacitinib API. The other chloride leaving group is to be reacted with the three-membered ring scaffold (CAS No. 6228-73-5), Deucravacitinib API.
Zhuang, L. et al. Tyrosine Kinase 2 Inhibitors, Preparation Methods and Medicinal Uses Thereof. (2022).
Liu, J. et al. Tyrosine Kinase 2 (tyk2) Degradation Compounds and Methods of Use. (2022).
Greenwood, J. R. et al. Tyk2 Inhibitors and Uses Thereof. (2018).
Šagud, I. et al. Solid State Forms of Deucravacitinib, Deucravacitinib Hcl and Process for Preparation of Deucravacitinib and Intermediates. (2023).
Chen, K. et al. Process for the Preparation of 6-(cyclopropaneamido)-4-((2-Methoxy-3-(1-Methyl-1h-1,2,4-Triazol-3-Yl)phenyl)amino)-N-(methyl-D3)pyridazine-3-Carboxamide. (2018).
Li, P., Wang, P., Zhou, P., Zhao, X. & Wei, Q. Method for Synthesizing Deucravacitinib. (2024).
Wang, W. et al. Hydroxamate Compound, Preparation Method Therefor and Application Thereof. (2022).
Wrobleski, S. T. et al. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. J. Med. Chem. 62, 8973–8995 (2019).
Chen, X. & Pang, Y. Heterocyclic Compounds for Inhibiting Tyk2 Activities. (2021).
Du, J. & Guo, L. Crystal Form of Pyridazine Derivative Free Base, and Preparation Method Therefor and Use Thereof. (2022).
Li, H., Li, Z., Zhou, J., Xu, J. & Zhang, Q.-Y. Compounds and Methods for Inhibiting Viral Replication and Methods of Treating and Preventing Flaviviral Infections. (2022).
Moslin, R. M., Weinstein, D. S., Wrobleski, S. T., Tokarski, J. S. & Kumar, A. AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES. (2014).
Brimert, T., Johnsson, R., Leffler, H., Nilsson, U. & Zetterberg, F. Alpha-D-Galactoside Inhibitors of Galectins. (2016).
